Cantor Fitzgerald initiated coverage with an overweight rating and price target for a company debuting on the New York Stock Exchange.
1 report, 1 independent
Updated Sep 21
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Cantor Fitzgerald initiated coverage with an overweight rating and price target for a company debuting on the New York Stock Exchange.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Cantor Fitzgerald
American financial services company
-
New York Stock Exchange
American stock exchange
Related events
- Cantor Fitzgerald initiated coverage with an Overweight rating and authorized trading of tokenized securities.
- Cantor Fitzgerald raised its price target and rating for Supernus Pharmaceuticals, Inc. on September 2, 2026, and the company filed a disclosure with the SEC.
- MarketBeat reports consensus rating and price target for Eikon Therapeutics, Inc., alongside rating updates from Cantor Fitzgerald and Manufacturers Life Insurance Company.
- Cantor Fitzgerald restated an overweight rating on shares, while J. Goldman & Co LP purchased a new stake in Annexon. Disclosure was made to the Securities and Exchange Commission.
- Cantor Fitzgerald began coverage and issued rating, and Morgan Stanley upgraded price objective and rating for Silence Therapeutics.